United Kingdom Genomic Biomarkers Market Insight
Published: 22 July 2026 | Report Format: Electronic (PDF) | Author: Aditi and Govind
The United Kingdom Genomic Biomarkers Market was valued at USD 1.12 Billion in 2025 and is projected to reach USD 3.08 Billion by 2035, expanding at a CAGR of 10.64% during the forecast period. Market growth is being supported by the increasing adoption of precision medicine, rising prevalence of cancer and rare genetic disorders, expanding genomic sequencing programs, growing pharmaceutical investment in biomarker-guided drug development, and continuous advancements in molecular diagnostics across the United Kingdom.
United Kingdom Genomic Biomarkers Market Forecasts to 2035
- The United Kingdom Genomic Biomarkers Market Size was estimated at USD 1.12 Billion in 2025.
- The market is expected to grow at a CAGR of 10.64% from 2025 to 2035.
- The United Kingdom Genomic Biomarkers Market Size is expected to reach around USD 3.08 Billion by 2035.
Notable Insights for the United Kingdom Genomic Biomarkers Market
- Segmentation Based on Biomarker Type, DNA Biomarkers accounted for the largest market share of approximately 46.8% in 2025, driven by their widespread application in oncology diagnostics, hereditary disease screening, pharmacogenomics, and precision treatment planning across hospitals and research institutions.
- Segmentation Based on Application, Oncology represented nearly 52.6% of total market revenue in 2025, supported by increasing adoption of companion diagnostics, expanding cancer genomic profiling programs, NHS precision medicine initiatives, and growing use of biomarker-guided targeted therapies.
- Illumina, Inc. reported USD 4.37 Billion in revenue during fiscal 2025, reflecting continued demand for next-generation sequencing platforms, genomic biomarker research solutions, clinical diagnostics, and precision medicine applications across global healthcare and life sciences markets.
Download the eBook (ToC)
- Thermo Fisher Scientific Inc. generated approximately USD 43.10 Billion in revenue during 2025, supported by strong sales of molecular diagnostics, genomic analysis technologies, biomarker discovery tools, and laboratory solutions serving pharmaceutical, biotechnology, and clinical research organizations worldwide.
Methodologies Used to Analyze the United Kingdom Genomic Biomarkers Market
This study combines primary and secondary research methodologies to evaluate the United Kingdom Genomic Biomarkers Market. Primary research includes interviews with genomic technology providers, molecular diagnostic laboratories, pharmaceutical companies, healthcare professionals, academic researchers, regulatory experts, and senior industry executives. Secondary research incorporates company annual reports, NHS publications, Genomics England reports, UK government healthcare statistics, peer-reviewed journals, industry associations, and commercial databases. Market estimates are developed using both top-down and bottom-up approaches, while data triangulation ensures accurate market sizing, competitive benchmarking, and long-term forecasting reliability.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Genomic Biomarkers Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Genomic Biomarkers Market
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation (Leica Biosystems & Cepheid)
- Guardant Health, Inc.
- Exact Sciences Corporation
- Oxford Nanopore Technologies plc.
Recent Developments:
- In October 2025, Illumina, Inc. launched an expanded multi-cancer genomic biomarker testing workflow for European clinical laboratories, including the United Kingdom, improving sequencing efficiency and accelerating precision oncology research and diagnostics.
- In June 2025, QIAGEN N.V. collaborated with AstraZeneca to advance companion diagnostic development using genomic biomarkers, supporting personalized oncology treatment strategies and strengthening precision medicine capabilities across European healthcare markets.
Market Segmentation
United Kingdom Genomic Biomarkers Market, By Biomarker Type
- DNA Biomarkers
- RNA Biomarkers
- Protein Biomarkers
- Epigenetic Biomarkers
- Others
United Kingdom Genomic Biomarkers Market, By Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Microarrays
- Immunoassays
- Others
United Kingdom Genomic Biomarkers Market, By Application
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Rare Genetic Diseases
- Infectious Diseases
- Others
United Kingdom Genomic Biomarkers Market, By End User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
United Kingdom Genomic Biomarkers Market, By Region
- England
- Scotland
- Wales
- Northern Ireland
Expert Views:
The United Kingdom Genomic Biomarkers Market is expected to record robust growth through 2035, driven by continued investment in genomic medicine, wider adoption of precision diagnostics, increasing biomarker-guided drug development, and expanding national sequencing initiatives. Companies focusing on advanced sequencing technologies, AI-enabled genomic analytics, and strategic clinical collaborations are expected to strengthen their market position while supporting the country's transition toward personalized healthcare
Author: Aditi and Govind By Decisions Advisors and Consulting